| HER2-Positive Breast Carcinoma studied in …STUDIED_INderived200 of 377show all (up to 200) |
|---|
| → studied in | NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05880160NA · completed Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07152782Phase 2 · recruiting T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | Early Stage HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03387553early Phase 1 · completed HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585750Phase 1/Phase 2 · recruiting The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05115474Phase 2 · recruiting Study of Screening Brain MRIs in Stage IV Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05378464Phase 1 · suspended Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05809752Phase 1 · active not recruiting A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05710328Phase 2 · active not recruiting Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05306041Phase 2 · recruiting Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04030507NA · active not recruiting Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899908Phase 2 · recruiting Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253871Phase 1 · recruiting A Phase 1/1b Study of IAM1363 in HER2 Cancers · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04704661Phase 1 · active not recruiting Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04886531Phase 2 · recruiting Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07413939Phase 2/Phase 3 · recruiting RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06557057recruiting Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06068985Phase 2 · active not recruiting Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768358Phase 4 · not yet recruiting Tucatinib Continuation Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06414733Phase 1 · recruiting HER-2 B Cell Peptide Vaccine · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06949410Phase 1 · recruiting HER2 Vaccine for Locally Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03644186Phase 2 · completed To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06123988NA · recruiting Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06891833Phase 2/Phase 3 · recruiting A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07787338Phase 2 · not yet recruiting SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04360941Phase 1 · active not recruiting PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05593094Phase 1/Phase 2 · active not recruiting A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441890Phase 2 · recruiting BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07459673Phase 2 · recruiting HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550494Phase 2 · active not recruiting Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04893109Phase 2 · recruiting ATEMPT 2.0: Adjuvant T-DM1 vs TH · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04332588Phase 1 · recruiting Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03696030Phase 1 · active not recruiting HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721248Phase 2 · active not recruiting STOP-HER2: Stopping Trastuzumab in HER2+ MBC · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748260Phase 3 · not yet recruiting De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02654119Phase 2 · completed Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445400Phase 2 · active not recruiting A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252887Phase 2 · completed Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07726342Phase 2 · not yet recruiting SMP-656 for HER2-Positive Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975647Phase 3 · active not recruiting A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06316531Phase 3 · active not recruiting A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06450314Phase 2 · recruiting Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07716046Phase 2 · not yet recruiting Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708194Phase 1/Phase 2 · recruiting Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07137416Phase 1 · recruiting Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03747120Phase 2 · active not recruiting Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06386263completed HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161922completed Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03179904Phase 2 · completed TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04273555Phase 1/Phase 2 · withdrawn Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07673029Phase 3 · recruiting A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07136493NA · withdrawn Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412459completed 99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217990Phase 1/Phase 2 · not yet recruiting Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05514717Phase 1 · terminated A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06892093NA · recruiting Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01730833Phase 2 · completed Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04517838recruiting Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04457596Phase 3 · active not recruiting T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647263Phase 2 · recruiting Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07635342Phase 2 · recruiting Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04638725recruiting Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518173Phase 3 · recruiting A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07616440NA · recruiting Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03199885Phase 3 · terminated Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05582499Phase 2 · recruiting Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05955833NA · completed 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578116Phase 3 · not yet recruiting Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04588545Phase 1/Phase 2 · active not recruiting Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03125928Phase 2 · active not recruiting Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07589699Phase 4 · not yet recruiting Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07053085Phase 2 · recruiting A Study of Surgery and Radiotherapy in People With Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06844669Phase 2 · terminated HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07581795Phase 2 · not yet recruiting Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319873Phase 1/Phase 2 · active not recruiting Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06968585Phase 3 · active not recruiting A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01042379Phase 2 · recruiting I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03738553terminated Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06172127Phase 2 · active not recruiting PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05705401Phase 3 · active not recruiting Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05969860Phase 2 · recruiting At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06518382recruiting Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02705859Phase 1 · completed Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07441460Phase 3 · recruiting A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07510802Phase 1/Phase 2 · recruiting Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04569747Phase 2 · active not recruiting A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07043725Phase 3 · recruiting A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04539938Phase 2 · completed A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07486089Phase 1/Phase 2 · recruiting Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07470203not yet recruiting Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03384914Phase 2 · active not recruiting Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07454668Phase 1 · not yet recruiting Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05325632Phase 2 · recruiting Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07421141Phase 2 · active not recruiting De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07377643Phase 3 · recruiting IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016387Phase 2 · recruiting Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06446882NA · recruiting Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07416409completed Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07417241Phase 2 · not yet recruiting SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348134Phase 2 · recruiting Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06744465NA · recruiting NearWave Optical Molecular Monitoring · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02226276NA · active not recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06435429Phase 3 · recruiting A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533670active not recruiting TME Alteration in HER2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07366840Phase 2/Phase 3 · not yet recruiting RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03368729Phase 1/Phase 2 · active not recruiting Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830889Phase 3 · recruiting A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07358182recruiting Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03879577Phase 2 · active not recruiting Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220214early Phase 1 · recruiting Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06210776recruiting A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04578106Phase 2 · terminated Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328465NA · recruiting fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05553522Phase 1 · terminated Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07281001NA · recruiting A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583110Phase 2 · terminated Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer · condition mapped CURATED_BROADER · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05253911completed Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03571633Phase 2 · active not recruiting Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05982678Phase 2 · recruiting Basket Study for Oligo-metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954143Phase 2 · terminated Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328738Phase 1 · active not recruiting ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07233499Phase 2 · recruiting Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04425018Phase 2 · active not recruiting MARGetuximab Or Trastuzumab (MARGOT) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02827877Phase 2 · active not recruiting Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07178938Phase 2 · not yet recruiting Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06265428Phase 3 · active not recruiting A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04419181Phase 2 · withdrawn Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05599334completed A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108858Phase 1/Phase 2 · terminated Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05036252active not recruiting Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07198672NA · not yet recruiting Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05760612Phase 3 · recruiting Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708910recruiting AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06087120recruiting Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05795101Phase 2 · recruiting TRUDI: TDXD+Durva in HER2+/Low IBC · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179939Phase 2 · not yet recruiting Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04249622Phase 2 · terminated Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04278144Phase 1/Phase 2 · terminated A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166367Phase 2 · terminated Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03588091Phase 3 · completed Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07116824Phase 2 · not yet recruiting HB1801 Combined Treatment of HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04487236Phase 1 · completed Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07115095NA · completed Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02003209Phase 3 · completed Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973525Phase 2 · not yet recruiting This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06358625recruiting Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755141Phase 2 · completed Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042051Phase 1 · terminated Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06992882Phase 3 · recruiting A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07073755recruiting Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01722890terminated CharactHer. ICORG 12-09, V3 · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01840306completed Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06833268completed Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05511844Phase 1 · terminated Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03094052Phase 2 · completed Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04220203approved for marketing Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04420598Phase 2 · completed DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030569recruiting RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07019272not yet recruiting Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07019337Phase 2 · not yet recruiting Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05346224Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04789096Phase 2 · terminated Tucatinib Together With Pembrolizumab and Trastuzumab · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06958627Phase 2/Phase 3 · recruiting The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01785420Phase 3 · recruiting Pre Operative Trastuzumab in Operable Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05406635NA · recruiting Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00436254Phase 1 · completed Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05252988Phase 2 · active not recruiting Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03460067NA · active not recruiting Omission of Radiation in Patients With Her-2 Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05955170Phase 2 · recruiting Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802876Phase 2 · active not recruiting Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868758active not recruiting Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868017Phase 4 · not yet recruiting Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05918328Phase 2 · recruiting Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246671Phase 1 · completed TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020860Phase 2 · recruiting Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03715959NA · completed Nipple Aspirate Fluid in Detecting Breast Cancer · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06832904Phase 2 · recruiting Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03133988approved for marketing Margetuximab Expanded Access Program · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06821490enrolling by invitation Validation of TAD in HER-2 with More Than 2 Lymph Nodes · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05388149Phase 2 · recruiting Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03881605NA · active not recruiting MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06782698NA · active not recruiting Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06754059recruiting Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05904730Phase 1 · completed Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981705completed Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04660929Phase 1 · unknown CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06276868Phase 2 · recruiting Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05555251Phase 1/Phase 2 · terminated BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06718335NA · not yet recruiting Pyrotinib in HER2-positive Early Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06722599recruiting Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06722612recruiting Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04675827Phase 2 · terminated De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06711055recruiting Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06711068recruiting Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy · condition mapped ALIAS · 377 trials mapped (167 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |